KetaMD’s mission is to expand access and awareness to psychedelic medicine treatment at a time when mental health issues are devastating people across the world
September 21, 2022 ― KetaMD, a Florida-based telemedicine company providing access to at-home ketamine treatments for people suffering from depression and related mental health conditions, has been acquired by Toronto-based Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders. With this recent acquisition, KetaMD is now available in the State of Florida with a rollout to other key states planned next year.
KetaMD’s end-to-end telemedicine platform, utilizing leading technology and a mobile app, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions. Treatments are medically supervised, guided virtually by registered nurses, and backed by the world’s leading psychiatrists and researchers in depression.
Braxia Scientific plans to further augment the KetaMD platform, including planning new clinical trials in the U.S. and leveraging Braxia’s growing proprietary patient dataset, to support the potential future development of psychedelic therapeutics in the management of depression and other related mental health conditions. KetaMD’s innovative technology capabilities provide Braxia the opportunity to offer both in-person and digital telehealth ketamine treatments, combined with established clinical research and development capabilities focused on the commercialization and real-world implementation of novel pharmaceuticals.
“The KetaMD team is honored to have the opportunity to work with Braxia CEO Dr. McIntyre and a world-leading research team at Braxia Scientific in the area of depression and mood disorders,” said Warren Gumpel, CEO and Co-Founder of KetaMD. “I believe this will be the key distinguishing factor in KetaMD’s success.”
“This acquisition is a notable step forward in bringing awareness, accessibility, and scalability of the benefits of ketamine and psychedelics generally for those suffering from depression and other mood disorders,” said Dr. Roger McIntyre, CEO, Braxia Scientific. “We’ve seen improved outcomes firsthand from ketamine treatment in our clinics and in our clinical trials. Adding digital telehealth capabilities through KetaMD’s online and mobile platform strengthens our position to lead the medical use of evidence-based psychedelics, while accelerating our ability to get treatment to those in need, safely and quickly across the U.S. and Canada, and globally in the future.”
KetaMD was founded by psychedelic pioneers Zappy Zapolin and Warren Gumpel, along with mindfulness instructor and brand experience expert Kaia Roman and the company’s President and Chief Operating Officer, Leann Taylor. The team are dedicated to helping those suffering from debilitating mental health issues find relief through ketamine and other novel psychedelic medicines.
For those interested in qualifying for KetaMD are encouraged to visit www.KetaMD.com and download the KetaMD app.
About KetaMD
KetaMD is a HIPAA-compliant telemedicine platform providing affordable and potentially life-changing at-home medical ketamine treatments. Prescribed by medical professionals and guided by registered nurses via a secure platform and mobile app, KetaMD is a safe and effective alternative for the millions of adults that currently suffer from depression, anxiety, and related mental health challenges. The company’s mission is to make ketamine treatment safely accessible to those who need it across the United States. Through KetaMD’s program, adults who receive a qualifying diagnosis a licensed medical prescriber may participate in the fully virtual program. For more information, visit www.ketamd.com.
About Braxia Scientific Corp.
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine and psilocybin treatments for people with depression and related disorders. Braxia also launched its U.S. based end-to-end telemedicine platform KetaMD utilizing leading technology to provide access to safe, affordable, and potentially life-changing at-home ketamine treatments for people living with depression and related mental health conditions. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatments in-person and virtually for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, Braxia Health (formerly the Canadian Rapid Treatment Center of Excellence Inc.), operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.
